Effect of the Modified Live Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) Vaccine on European and North American PRRSV Shedding in Semen from Infected Boars

Kiwon Han,† Hwi Won Seo,† Jeoung Hwa Shin,‡ Yeonsu Oh,‡ Ikjae Kang,† Changhoon Park,‡ and Chanhee Chae†*

Department of Veterinary Pathology, College of Veterinary Medicine, Seoul National University, 599 Gwanak-ro, Gwanak-gu, Seoul 151-742, Republic of Korea,† and Korea Basic Science Institute, Environmental and Metabolomics Research Team, 126-16 Anam-dong, Seongbuk-gu, Seoul 136-713, Republic of Korea‡*

Received 8 June 2011/Returned for modification 12 July 2011/Accepted 2 August 2011

The objective of the present study was to compare the effects of the modified live porcine reproductive and respiratory syndrome virus (PRRSV) vaccine (Ingelvac PRRS MLV; Boehringer Ingelheim Animal Health, St. Joseph, MO) on European and North American PRRSV shedding in the semen of experimentally infected boars. The boars were randomly divided into six groups. Vaccinated boars shed the North American PRRSV at the rate of \(10^{0.6} \) to \(10^{1.0}\) viral genome copies per ml and \(3.63 \) to \(10^{1.1}\) 50% tissue culture infective doses (TCID\(_{50}\))/ml, respectively, in semen, whereas nonvaccinated boars shed the North American PRRSV at the rate of \(10^{0.2} \) to \(10^{4.7}\) viral genome copies per ml and \(1.14 \) to \(10^{5.97}\) TCID\(_{50}\)/ml, respectively, in semen. Vaccinated boars shed the European PRRSV at the rate of \(10^{0.1} \) to \(10^{5.57}\) viral genome copies per ml and \(1.66 \) to \(10^{6.10}\) TCID\(_{50}\)/ml, respectively, in semen. Vaccinated boars shed the European PRRSV at the rate of \(10^{5.3}\) to \(10^{6.14}\) viral genome copies per ml and \(1.69 \) to \(10^{3.17}\) TCID\(_{50}\)/ml, respectively, in semen. The number of genomic copies of the European PRRSV in semen samples was not significantly different between vaccinated and nonvaccinated challenged European PRRSV boars. The present study demonstrated that boar vaccination using commercial modified live PRRSV vaccine was able to decrease subsequent shedding of North American PRRSV in semen after challenge but was unable to decrease shedding of European PRRSV in semen after challenge.

**Porcine reproductive and respiratory syndrome virus (PRRSV)** is a member of the genus *Arterivirus*, the family *Arteriviridae*, and the order *Nidovirales*. The virus contains a positive single-stranded polyadenylated RNA approximately 15 kb in length that contains nine open reading frames (ORFs). The virus infects porcine cells and growth-completing pigs and reproductive failure in sows and boars (3, 4, 6, 7, 9, 24, 27).

Although PRRSV was first isolated in Korea in 1994 (14) and all PRRSV isolates corresponded to the North American genotype until 2000 (5), European PRRSV has recently emerged in Korea (13, 17, 21). The company claims that modified live PRRSV vaccine can cross-protect against challenge of both European and North American genotypes (Ingelvac PRRS MLV package insert; Boehringer Ingelheim Animal Health, St. Joseph, MO [http://bi-vetmedica.com/sites/default/files/ingelvac_PRRS_MLV_rp.pdf]). However, a large number of abortions caused by the European PRRSV genotype occurred in a swine herd in which sows and gilts had been vaccinated for 3 years under a whole-herd vaccination program. All pregnant and nonpregnant sows and all gilts were vaccinated every 4 months according to the manufacturer’s recommendation (personal observation). Although this outbreak was not related to European genotype PRRSV-contaminated semen, this incident raised the possibility that the modified live PRRSV vaccine could not protect against the European PRRSV genotype isolated in Korea. Furthermore, studies have shown mixed results regarding the efficacy of this commercial vaccine against the genetically diverse field strains of PRRSV (18). Hence, the impact of European PRRSV genotype-contaminated semen is enhanced due to its widespread distribution throughout the Korean swine industry, even though boars in commercial artificial insemination centers have already been vaccinated with modified live PRRSV. Although it has been reported that modified live PRRSV vaccination reduced the subsequent shedding of European and North American genotypes of PRRSV in boars (8, 22), the objective of the present study was to compare the effects of boar vaccination on North American and European genotype challenges, including the reduction of subsequent virus shedding in semen.

**MATERIALS AND METHODS**

**Commercial vaccine and PRRSV inocula.** The commercial modified live PRRSV vaccine (Ingelvac PRRS MLV; Boehringer Ingelheim Animal Health) was used in this study. Boars were vaccinated with a 2.0-ml dose intramuscularly as previously described (8, 22).
European (SNL090485) and North American (SNU090851) PRRSV strains were used as inocula. The European PRRSV strain was isolated in lung samples from an aborted fetus and neonatal pigs in 2009 in Kyounggi Province. The North American PRRSV strain was isolated in lung samples from a postweaning pig in 2009 in Chungcheong Province. The nucleotide sequence homology in ORF5 between the European PRRSV strain (GenBank accession number JN315666) and the vaccine strain (GenBank accession number AF355152) is 68%, and between the North American PRRSV strain (GenBank accession number JN315685) and the vaccine strain it is 86%, using BioEdit, version 7.0.0 (Bis Biosciences, Carlshad, CA [http://www.mbio.ncsu.edu/BioEdit/bioedit.html]). Each virus (passage 6) was propagated in MARC-145 cells to a titer of 1 × 10^5.5% tissue culture infective doses (TCID_{50})/ml.

**Experimental design.** At 6 months of age, 30 purebred male Landrace pigs were purchased from a PRRSV-free commercial farm. All boars were negative for porcine circovirus type 2 (PCV2) and PRRSV according to routine serological testing prior to delivery and on arrival. All boars were individually housed throughout the experiment in an environmentally controlled building with pens over completely slatted floors. The boars were randomly divided into six groups. The boars in group 1 ([T01] n = 5) were immunized with modified live PRRSV vaccine with single 2.0-ml doses. Six weeks after vaccination (42 days postinoculation [dpi]), these boars were inoculated with European PRRSV intranasally (1 ml) with an infectious titer of 10^5 TCID_{50} per ml. The boars in group 2 ([T02] n = 5) were immunized with modified live PRRSV vaccine with single 2.0-ml doses. Six weeks after vaccination (42 dpi), these boars were inoculated with North American PRRSV intranasally (1 ml) with an infectious titer of 10^6 TCID_{50} per ml (0 dpi). The boars in group 3 ([T03] n = 5) were inoculated with European PRRSV intranasally (1 ml) with an infectious titer of 10^6 TCID_{50} per ml (0 dpi). The boars in group 4 ([T04] n = 5) were inoculated with North American PRRSV intranasally (1 ml) with an infectious titer of 10^5 TCID_{50} per ml (0 dpi). The boars in group 5 ([T05] n = 5) were immunized with modified live PRRSV vaccine with single 2.0-ml doses. The boars in group 6 ([T06] n = 5) served as negative controls and were exposed to neither vaccine nor virus. Following PRRSV inoculation, the physical conditions of the boars were monitored daily, and their rectal temperatures were taken. All of the methods were previously approved by the Seoul National University Institutional Animal Care and Use Committee.

**Serology.** Blood samples from each pig were collected by jugular venipuncture at −42, −21, 0, 14, 21, 28, 35, 42, 49, and 60 dpi, and the sera were stored at −20°C. The serum samples were tested using a commercially available PRRSV enzyme-linked immunosorbent assay ([ELISA] HerdCheck PRRS 2XR; Idexx Laboratories Inc., Westbrook, ME). The virus isolation. Blood and semen (raw) samples were collected for virus isolation at −42, −21, −7, 0, 4, 7, 10, 14, 18, 21, 25, 28, 32, 35, 39, 42, 46, 49, 53, 56, and 60 dpi from all boars used in this study. PRRSV was isolated from serum and semen as previously described (9, 12). Virus titrations were also performed in confluent monolayers of MARC-145 cells in 96-well plates as previously described (12).

**Sequence analysis.** The PRRSV isolates from semen were further analyzed for the ORF5 sequence. RNA was extracted from PRRSV-infected MARC-145 cell lines (4) and amplified from the ORF5 region by reverse transcription-PCR (RT-PCR) (23). Sequencing was performed on the purified RT-PCR products of amplified ORF5.

**Real-time PCR.** Real-time PCR for the European and North American PRRSVs was performed as previously described (26). Real-time PCR for the vaccine strain was performed in this study based on ORF5 because the nucleotide sequence homology in ORF5 between the challenging North American PRRSV strain (SNL090851) and the vaccine strain is 86%, using BioEdit, version 7.0.0 (Bis Biosciences). Primers and probes were used for PRRSV quantitation in real-time PCR with hybridization probes that were based on the sequence of the PRRSV plasmid as the standard, with concentrations ranging from 10^{10} to 10^{3} copies/ml or 10-fold serial dilutions of the European and North American PRRSVs cultured in MARC-145 cells from 10^5 TCID_{50}/ml to 10^{-1} TCID_{50}/ml or 10-fold serial dilutions of the vaccine strain cultured in MARC-145 cells from 10^5 to 10^{-5} TCID_{50}/ml. The PRRSV plasmid was prepared as described previously (10). Briefly, the transcript cDNA product was cloned into the pCR2.1 plasmid (Invitrogen, Carlsbad, CA). The recombinant plasmid was purified using a plasmid Miniprep Kit (Qiagen, Valencia, CA) according to the manufacturer’s instructions, and the concentration of the purified plasmid was determined using a spectrophotometer.

**Interference.** Potential interference from detecting the two viruses simultaneously was examined by mixing their RNAs together in one reaction tube. The sensitivity for the detection of one or both virus types was evaluated.

**Statistical analysis.** Summary statistics were calculated for the six groups to assess the overall quality of the data, including normality. For a single comparison of PRRSV RNA quantification, Student’s t test for paired samples (European and North American PRRSV RNA quantification) was used to estimate the difference at each time point. Continuous data for PRRSV serology over time between the groups were analyzed at each time point using a Mann-Whitney U test. The Pearson correlation coefficient was used to assess the relationship of PRRSV RNA load between blood and semen. A value of 0.05 was considered significant.

**RESULTS**

**Clinical signs.** Vaccinated boars (groups T01, T02, and T05) and negative-control boars (T06) were clinically normal in health and rectal temperatures (38 to 39.5°C) throughout the experiment, whereas in nonvaccinated boars (T03 and T04) daily rectal temperatures increased (39.1 to 39.3°C) after PRRSV challenge. Some nonvaccinated boars (T03 and T04) were depressed and anorectic for approximately 3 days after PRRSV challenge.

**Serology of PRRSV.** Anti-PRRSV antibodies were detected in serum samples at 3 weeks postvaccination (−21 dpi) in vaccinated boars (groups T01, T02, and T05) only. In nonvaccinated boars (T03 and T04), no anti-PRRSV antibodies were detected in serum samples until challenge (0 dpi). As expected, no anti-PRRSV antibodies were detected in serum from the negative-control boars (T06) throughout the experiment (data not shown).

**Specificity of real-time PCR.** Primers from the vaccine strain did not react with challenging European (SNL090485) and North American (SNU090851) PRRSV strains. Primers from the vaccine strain did not react with the North American PRRSV strain, but primers from the North American PRRSV strain did react with the vaccine strain (data not shown).

**Standard curve.** Standard curves were constructed by plotting the logarithm of the copy number of the 10-fold serially diluted plasmid against the measured CT values. The linear correlation (R^2) between the CT and the logarithm of the plasmid copy number were repeatedly greater than 0.998 for the European PRRSV, 0.997 for the North American PRRSV, and 0.995 for the vaccine strain (data not shown).

**Interference.** To determine whether having the two types of viruses present in the same sample interferes with the standard curve, detection of the viral copies of one or the other type was performed. The detection of the North American PRRSV was found to be efficient and sensitive, independent of a combina-
tion of the North American PRRSV with the same TCID$_{50}$/ml of the European PRRSV per tube (Fig. 1A), whereas the detection of the European PRRSV was somehow less sensitive when the same TCID$_{50}$/ml of the North American PRRSV per tube was present, which demonstrated a reduction in the correlation coefficient of the slope of the RNA standard to 98.4% for European PRRSV detection (Fig. 1B). The detection of the vaccine strain was found to be efficient and sensitive, independent of a combination of the vaccine strain with the same TCID$_{50}$/ml of European PRRSV per tube, whereas the detection of the European PRRSV was somehow less sensitive when the same TCID$_{50}$/ml of vaccine strain per tube was present, which demonstrated a reduction in the correlation coefficient of the slope of the RNA standard to 98.8% for European PRRSV detection. The detection of the vaccine strain was somehow less sensitive when the same TCID$_{50}$/ml of North American PRRSV per tube was present, which demonstrated a reduction in the correlation coefficient of the slope of the RNA standard to 98.2% for vaccine strain detection.

**Virus isolation and sequence analysis in blood and semen.** Attempts were made to isolate and identify the European and...
North American PRRSVs and the vaccine strain from the serum and semen of the five groups (Table 1). No PRRSV was isolated from the serum and semen of the negative-control boars (group T06). The vaccine strain was isolated only from the serum and semen of the vaccinated boars (groups T01, T02, and T05) before challenge (0 dpi), and thereafter vaccine strains were not isolated from any serum and semen samples from the vaccinated boars (groups T01, T02, and T05) before challenge (0 dpi), and thereafter vaccine strains were not isolated from any serum and semen samples from the vaccinated boars (groups T01, T02, and T05). All isolated PRRSV was confirmed to be the same propagating virus in the challenge stock by sequence analysis.

**Log_{10} TCID_{50}/ml quantification and real-time PCR of PRRSV RNA in serum.** Genomic copies of the European, North American, and vaccine PRRSV strains were not detected in the serum samples at −42 dpi for all groups. No genomic copies of the European PRRSV were observed in the serum samples from vaccinated, challenged North American PRRSV boars (T02), from nonvaccinated, challenged North American PRRSV boars (T04), or from vaccinated, nonchallenged boars (T05). We measured no genomic copies of the North American PRRSV in the serum samples from the vaccinated, challenged European PRRSV boars (T01), from the nonvaccinated, challenged European PRRSV boars (T03), or from the vaccinated, nonchallenged boars (T05). The vaccine strain was detected until −14 dpi only in the serum samples from vaccinated, challenged European PRRSV boars (T01), from vaccinated, challenged North American PRRSV boars (T02), and from vaccinated, nonchallenged boars (T05) (Fig. 2A and B). No PRRSV was observed in the serum samples from the negative control (T06) boars throughout the experiment.

For the intergroup comparison, the number of genomic copies and the log_{10} TCID_{50}/ml of the European PRRSV were not significantly different in the serum samples from vaccinated, challenged European PRRSV boars (T01) from values in samples from nonvaccinated, challenged European PRRSV boars (T03) (Fig. 2). The mean viral titers in serum expressed as log_{10} TCID_{50}/ml and the number of genomic copies of the North American PRRSV were lower in the serum samples from the vaccinated, challenged North American PRRSV boars (T02) than in the serum samples from the nonvaccinated, challenged North American PRRSV boars (T04) at 7 (P = 0.005), 10 (P = 0.002), 14 (P = 0.005), 18 (P < 0.000), and 21 (P = 0.001) dpi for TCID_{50}/ml and at 4 (P = 0.002), 7 (P = 0.001), 10 (P = 0.001), 14 (P = 0.001), 18 (P = 0.001), 21 (P = 0.001), 25 (P < 0.000), 28 (P = 0.008), and 32 (P = 0.004) dpi for the number of genomic viral copies.

For the intergroup comparison, the numbers of genomic copies and the log_{10} TCID_{50}/ml of the European PRRSV in the semen samples did not significantly differ between the vaccinated, challenged European PRRSV boars (T01) and the nonvaccinated, challenged European PRRSV boars (T03) (Fig. 3). The mean viral titers in the semen expressed as log_{10} TCID_{50}/ml and the number of genomic copies of the North American PRRSV were significantly lower in the semen sam-
The number of genomic copies of PRRSV RNA in the semen samples did not correlate with the blood genomic copy number in vaccinated, challenged European PRRSV boars (T01; Spearman correlation coefficient $r_s = 0.542$), in vaccinated, challenged North American PRRSV boars (T02; $r_s = 0.499$), in nonvaccinated, challenged European PRRSV boars (T03; $r_s = 0.694$), or in nonvaccinated, challenged North American PRRSV boars (T04; $r_s = 0.688$).

DISCUSSION

The present study has demonstrated that the vaccination of boars by commercial modified live vaccine decreased subsequent shedding of the North American PRRSV after challenge but was unable to decrease the shedding of the European PRRSV in the semen after challenge. These results indicated...
that the North American PRRSV-based modified live vaccine is more effective against homologous challenges than against heterologous challenges. These results agree with previous findings in which less heterologous protection was observed in a trial that included the challenge of pregnant sows than in homologous challenge with the same vaccine (16). Moreover, vaccination with this vaccine barely reduced the level of viremia after challenge with the European PRRSV in preweaning pigs (25). In the present study, vaccinated boars (groups T01, T02, and T05) shed the vaccine PRRSV strain only during the first 21 days postvaccination. These results are similar to those of a previous study (8).

Vaccinated boars shed the North American PRRSV at the rate of $10^{0.2}$ to $10^{1.7}$ viral genome copies per ml and 3.63 to $10^{1.1}$ 50% tissue culture infective doses (TCID$_{50}$/ml, respectively, in semen, whereas nonvaccinated boars shed the North American PRRSV at the rate of $10^{0.1}$ to $10^{1.0}$ viral genome copies per ml and $1.14$ to $10^{3.07}$ TCID$_{50}$/ml, respectively, in semen. Thus, vaccination of boars reduced the shedding of North American PRRSV by approximately 99.7% in the semen compared to nonvaccinated boars. These results agree with a previous study that showed that boars are protected from the North American PRRSV shedding in the semen after vaccination (8). The reduction in PRRSV cDNA shedding is...
meaningful because the dose of viruses in semen plays a major role in the transmissibility of the PRRSV. For example, the North American PRRSV can be transmitted through extended semen depending on the dose of the virus. One out of five gilts North American PRRSV present in semen from vaccinated boars may minimize the transmission of North American PRRSV to sows via artificial insemination.

Vaccinated boars shed the European PRRSV at the rate of \(10^{9.1}\) to \(10^{5.57}\) viral genome copies per ml and 1.66 to \(10^{3.17}\) TCID\(_{50}\)/ml, respectively, in semen, whereas nonvaccinated boars shed the European PRRSV at the rate of \(10^{6.3}\) to \(10^{8.14}\) viral genome copies per ml and 1.69 to \(10^{3.17}\) TCID\(_{50}\)/ml, respectively, in semen. Thus, vaccination of boars reduced the shedding of European PRRSV by only 11.1% in the semen compared to nonvaccinated boars. These observations are in contrast with a Danish study (22) in which European PRRSV (Danish isolate) shedding was significantly reduced after heterologous challenge in boars that were immunized with the same vaccine used in this study (22). We have no clear explanation for this discrepancy, but it may be due to antigenic variation between two European genotypes. Because the ORF5 and ORF7 nucleotide sequences in the Korean isolate (European genotype) are 88% and 91% identical, respectively, to the Danish European PRRSV isolate (PRRSV 18794/93; GenBank accession numbers AY035906.1 for ORF5 and AY035951.1 for ORF7) used in a previous study (22), this genetic divergence may indicate that the two European PRRSVs are antigenically different. In addition, the genetic diversity within the European PRRSV may affect the efficacy of the European-type vaccine (15). However, in the present study, the antigenic difference was not proven. Further study is needed to determine the antigenic difference between Korean and Danish European PRRSV strains to explain the various degrees of shedding reduction in the semen that result from the application of the same North American-commercial vaccine against the different European genotype PRRSV strains.

The low efficiency of the North American PRRSV-based vaccine used in this study for reducing European PRRSV shedding is clinically significant information although this study used extra label for the vaccine. Practitioners and producers should note that under field conditions, a modified live vaccine may not efficiently reduce the shedding of some European PRRSV strains in boars even if the boars are vaccinated in a whole-herd vaccination program in which all boars are vaccinated every 3 to 4 months, similar to a sow vaccination program. Therefore, it is strongly recommended that regular surveillance of the European PRRSV genotype in the semen is undertaken in countries where both genotypes of PRRSV coexist.

ACKNOWLEDGMENTS

This research was supported by contract research funds of the Research Institute for Veterinary Science from the College of Veterinary Medicine and by Brain Korea 21 Program for Veterinary Science in the Republic of Korea.

REFERENCES


